A short social explainer grouping antidiabetic medicines by their effect on body weight, from drugs linked to gain to those linked to loss.
Recap by typeshit. Post by @dr.medcortex on Instagram.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Bettervits reports CBL-514 aims to kill fat cells rather than shrink them, with early human trial results it calls promising. Research is still ongoing.
Nick Norwitz MD PhD breaks down new work where scientists built what he calls a living drug, and explains why he links it to GLP-1 in a five-part thread.
Loading…